PCa Commentary | Volume 147 – November 2020
This Commentary discusses how olaparib and rucaparib offer a needed additional treatment option for men with mCRPC.
Read MoreSelect Page
Posted by David Utz | Nov 2020
This Commentary discusses how olaparib and rucaparib offer a needed additional treatment option for men with mCRPC.
Read MorePosted by David Utz | May 2020
Culley C. Carson III, MD, Emeritus Rhodes Distinguished Professor in the Department of Urology at the University of North Carolina School of Medicine, discusses innovations in the treatment of male urinary incontinence. He outlines different treatments and their various pros and cons, including some cutting-edge technology that is not yet available in the US. He also goes over innovations, which still need to be made in order to further improve certain technologies like the artificial urinary sphincter. He highlights how important it is to come up with a more cost-effective model because, currently, artificial urinary sphincters are extremely expensive. There are also several significant causes of revision surgery for artificial urinary sphincters, demonstrating the need for further innovation. Dr. Carson also emphasizes the importance of customizing the pumps to individual patients, and goes over current research intended to improve patient outcomes.
Read MorePosted by David Utz | May 2020
Diet, Exercise + Prostate Cancer This interview, “Diet, Exercise + Prostate Cancer,”...
Read MorePosted by David Utz | May 2020
L. Michael Glodé, MD, FACP, Professor Emeritus at the University of Colorado Cancer Center and a medical oncologist at the Shaw Regional Cancer Center in Edwards, Colorado, discusses the mechanism of action of the TMPRSS2 and ACE2 pathways, and their relationship to the host-cell entry of COVID-19. He goes on to discuss a clinical trial using the serine protease inhibitor Camostat, noting how 5ARIs and GNRH analogues could act as a target for prevention and possible treatment of COVID-19. He also discusses the results of an Italian observational study which demonstrated how prostate cancer patients receiving ADT appear to be partially protected from COVID-19 infection.
Read MorePosted by David Utz | May 2020
Radiation, Immunotherapy + the Abscopal Effect This interview, “Radiation, Immunotherapy +...
Read More